Ocugen’s Leap into Phase 3 Trials: A Beacon of Hope for Retinitis Pigmentosa Patients
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company at the forefront of gene therapy innovation, has recently announced a groundbreaking development in the fight against retinitis pigmentosa (RP), …
Ocugen’s Leap into Phase 3 Trials: A Beacon of Hope for Retinitis Pigmentosa Patients Read More